Tag Archives: Sanofi
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Ben Comer | Published: September 13, 2012
The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28. Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – […]
By Ben Comer | Published: June 19, 2012
Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”
By Ben Comer | Published: April 25, 2012
Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon. Genzyme execs didn’t go so far as to reiterate former CEO Henri Termeer’s 2010 prediction of $3 billion plus in potential sales for Lemtrada (alemtuzumab), but they […]
By Ben Comer | Published: February 7, 2012
At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.